Jam

Hemostemix (HMTXF) has contracted Empire Market Ventures (EMV) to boost its market awareness. EMV, a New York-based consulting firm specializing in investor relations and strategic communications, will develop and implement investor engagement strategies using digital media and market intelligence. EMV will operate independently to provide unbiased counsel and ensure regulatory compliance. The goal of the partnership is to increase Hemostemix’s visibility and growth within the capital markets. The announcement was made on August 12, 2025.

ETHZilla (formerly 180 Life Sciences) announced it has accumulated 82,186 ETH, valued at approximately $349 million, with an average purchase price of $3,806.71. The company also maintains $238 million in USD cash equivalents. ETHZilla plans to generate yield from its ETH holdings through staking strategies managed by Electric Capital. The company is pivoting towards software-enabled gaming and entertainment, aiming to be a leader in on-chain treasury management and will provide regular updates on its progress.

Merck’s KEYNOTE-905 (EV-303) trial showed positive results for muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin-based chemotherapy. The study combined KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) before and after surgery, demonstrating statistically significant and clinically meaningful improvement in event-free survival (EFS), overall survival (OS), and pathologic complete response (pCR) compared to surgery alone. This represents the first systemic therapy to improve survival in this population, potentially establishing a new standard of care. The treatment’s safety profile was consistent with existing data.

E3 Lithium Ltd. is nearing completion of Phase 1 of its Demonstration Facility in Alberta, Canada, focused on Direct Lithium Extraction (DLE). All major equipment is assembled, and infrastructure integration is underway. Commissioning, starting with brine introduction to optimize the DLE system, is targeted for late August. The facility aims to produce high-quality lithium chloride for battery-grade lithium carbonate production. E3 Lithium holds a substantial lithium resource base and a promising Pre-Feasibility Study on its Clearwater Project.

DigitalOcean priced $550M in convertible senior notes due 2030, up from $500M, in a private offering. They’ll use $73.81M for capped call transactions against dilution and the rest with term loans to repurchase $1,131.3M of existing 2026 notes, extending repayment & potentially benefiting from interest rates. Initial conversion is 25.5317 shares/$1,000 note (39.17/share, 32.5% premium). DOcan redeem notes starting 2028 if share price exceeds 130% conversion price. A new $100M stock repurchase program was also authorized.

Ligand Pharmaceuticals (LGND) priced $400M convertible senior notes due 2030 in a private placement. The notes have a 0.75% interest rate and an initial conversion price of $194.79 per share, a 32.5% premium. Ligand expects $386.9M net proceeds, using $39.9M for hedge transactions, $15M to repurchase shares, and the rest for corporate purposes. The notes can be converted under certain conditions, and Ligand may redeem them after October 2028 if its stock price reaches 130% of the conversion price.

Cablevisión Holding (CVHSY) reported its First Half 2025 results, highlighting the acquisition of Telefónica Móvil Argentina (TMA). Total revenues increased 44.4% YoY to Ps. 3,357,004 million, driven by TMA integration and higher ARPUs. EBITDA rose 45.2% to Ps. 1,000,447 million, with a margin of 29.8%. However, the company reported a consolidated net loss of Ps. 80,188 million. 1H25 results are not directly comparable to 1H24 due to TMA’s inclusion. Excluding TMA, total costs decreased by 0.6% YoY.

Revive Therapeutics (RVVTF) closed the first tranche of its private placement, raising $60,900 by issuing 2.9 million units at $0.021 each. It also settled $67,400 in debt by issuing 3.2 million units at the same price. Each unit includes a share and a warrant exercisable at $0.05 for 36 months. The proceeds will fund working capital and payables. Securities are subject to a hold period expiring December 9, 2025. The offering included 100,000 compensation options to an investment dealer.

American Public Education, Inc. (APEI) has appointed James Kenigsberg as interim Chief Innovation and Technology Officer, signaling a strategic pivot towards AI-powered education. Kenigsberg, former CTO of 2U, Inc., will lead APEI’s efforts to integrate AI and data analytics across its educational network, including American Public University System, Rasmussen University, and Hondros College of Nursing. The goal is to enhance accessibility, improve student retention, and personalize learning experiences for students. APEI aims to become a data-first, AI-enabled institution.

TotalEnergies SE announced a share repurchase program, buying back 3,130,220 of its shares between August 4th and 8th, 2025, for over €163.5 million. The average weighted purchase price was €52.23 per share. Transactions were executed on AQEU, CEUX, XPAR, and TQEX exchanges. This buyback, authorized by shareholders, reflects confidence in TotalEnergies’ financial position and aims to enhance investor value. TotalEnergies focuses on providing sustainable energy solutions across oil, biofuels, gas, hydrogen, renewables, and electricity.